Sumitomo Dainippon Pharma Co., Ltd. Reports Consolidated Earnings Results for Nine Months Ended December 31, 2015 ; Revises Earnings Guidance for the Fiscal Year 2016 ; Provides Year End Dividend Guidance for the Year Ending March 31, 2016
January 27, 2016 at 10:00 am
Share
Sumitomo Dainippon Pharma Co., Ltd. reported consolidated earnings results for the nine months ended December 31, 2015. For the period, the company reported net sales of JPY 304,532 million compared to JPY 279,139 million a year ago. Operating income was JPY 31,086 million compared to JPY 22,818 million a year ago. Ordinary income was JPY 31,133 million compared to JPY 22,506 million a year ago. Net income attributable to owners of the parent of JPY 23,345 million compared to JPY 18,993 million a year ago. Earnings per share were JPY 58.76 compared to JPY 47.81 a year ago. Net income was JPY 23,345 million compared to JPY 18,993 million a year ago. Income before income taxes and minority interests was JPY 36,937 million compared to JPY 34,276 million a year ago. EBITDA was JPY 46.6 billion.
For the full year the company now expects net sales of JPY 403.0 billion, operating income of JPY 33.0 billion EBITDA of JPY 53.3 billion, net income attributable to owners of the parent of JPY 23.0 billion and ordinary income of JPY 32.5 billion and earnings per share to be JPY 57.89 compared to its previous forecast of net sales of JPY 401.0 billion, operating income of JPY 29.0 billion EBITDA of JPY 49.3 billion, net income attributable to owners of the parent of JPY 20.0 billion and ordinary income of JPY 23.3 billion and earnings per share to be JPY 50.34.
The company forecasts year end dividend of JPY 9.00 per share compared to JPY 9.00 a year ago.
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
Sumitomo Dainippon Pharma Co., Ltd. Reports Consolidated Earnings Results for Nine Months Ended December 31, 2015 ; Revises Earnings Guidance for the Fiscal Year 2016 ; Provides Year End Dividend Guidance for the Year Ending March 31, 2016
SUMITOMO PHARMA CO., LTD. 
